FHIR © HL7.org  |  Server Home  |  XIG Home  |  Server Source  |  FHIR  

FHIR IG Statistics: CodeSystem/v3-nciThesaurus

Packagehl7.terminology
TypeCodeSystem
Idv3-nciThesaurus
FHIR VersionR5
Sourcehttp://terminology.hl7.org/https://build.fhir.org/ig/HL7/UTG/CodeSystem-v3-nciThesaurus.html
URLhttp://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl
Version3.0.0
Statusactive
Date2022-10-13T00:00:00-04:00
NameNciThesaurus
TitleNCI Thesaurus
Realmuv
Authorityhl7
DescriptionNCI Thesaurus NCI Thesaurus is a biomedical thesaurus created specifically to meet the needs of the cancer research community, especially those engaged in translational research NCI Thesaurus is produced by the NCI Enterprise Vocabulary Services project. The NCI Thesaurus is provided under an open content license.
Contentnot-present

Resources that use this resource

CodeSystem
cmc-hierarchy-supplementPQ-CMC-FDA NCIt Hierarchy Supplement
ValueSet
PatientMilitaryStatusPatient Military Status
cdisc-yes-no-vsCDISC Yes No Unknown Not Applicable Value Set
ddf-study-title-type-vsCDISC DDF Study Title Type Value Set
m11-amendment-scope-enrollment-vsStudy Amendment Scope Enrollment Value Set
m11-identifier-type-vsM11 Identifier Type Value Set
m11-phase-vsM11 Phase Value Set
m11-section-codes-vsM11 Section Codes Value Set
m11-study-amendment-reason-vsStudy Amendment Reaason Value Set
m11-study-amendment-scope-vsStudy Amendment Scope Value Set
nci-study-role-vsNCI Study Role Value Set
mcode-all-risk-assessment-value-vsAcute Lymphoblastic Leukemia (ALL) Risk Assessment Value Set
mcode-binet-stage-value-vsBinet Stage Value Set
mcode-cancer-stage-type-vsCancer Stage Type Value Set
mcode-cancer-stage-value-vsCancer Stage Value Set
mcode-cancer-staging-method-vsCancer Staging Method Value Set
mcode-deauville-scale-vsDeauville Scale Value Set
mcode-figo-stage-value-vsFIGO Stage Value Set
mcode-international-retinoblastoma-stage-value-vsInternational Retinoblastoma Stage Value
mcode-lansky-play-performance-vsLansky Play Performance Status VS
mcode-lymphoma-stage-value-vsLymphoma Stage Value Set
mcode-lymphoma-staging-method-vsLymphoma Staging System Value Set
mcode-myeloma-iss-stage-value-vsInternational Staging System (ISS) for Myeloma Stage Value Set
mcode-myeloma-riss-stage-value-vsRevised International Staging System (ISS) for Multiple Myeloma Stage Value Set
mcode-neuroblastoma-INRGSS-value-vsInternational Neuroblastoma Risk Group Staging System (INRGSS) for Neuroblastoma Risk Assessment Value Set
mcode-pretext-stage-value-vsPRETEXT Stage Value
mcode-rai-stage-value-vsRai Stage Value Set
mcode-rai-staging-method-vsRai Staging System Value Set
mcode-rhabdomyosarcoma-assessment-value-vsRhabdomyosarcoma Assessment Value Set
mcode-rhabdomyosarcoma-clinical-group-value-vsRhabdomyosarcoma Clinical Group Value
mcode-risk-assessment-type-vsRisk Assessment Type Value Set
mcode-risk-assessment-vsRisk Assessment Value Set
mcode-tnm-staging-method-vsTNM Staging Method Value Set
adverse-event-clinical-research-causality-relatednessAdverse Event Clinical Research Causality Relatedness
adverse-event-clinical-research-gradesAdverse Event Clinical Research Grades
adverse-event-clinical-research-outcomesAdverse Event Clinical Research Outcomes
adverse-event-clinical-research-seriousness-criteriaAdverse Event Clinical Research Seriousness Criteria
propertyColorColor of the product
propertyFlavorFlavor of the product
propertyShapeShape of the product
DiagnosticMarkerDiagnostic Marker
HistologicalDiagnosisHistologicalDiagnosis
TumorGradeTumor Grade
TumorProgressionTumor Progression
TumorStageTumor Stage
phenotypic-abnormalityPhenotypic abnormality ValueSet
codexrt-radiotherapy-adverse-event-termVSAdverse Event Terms Value Set
valueset-businessOperationQualifiersBusiness Operation Qualifiers
valueset-establishmentBusinessOperationsEstablishment Business Operations
valueset-gdufaFacilityBusinessOperationQualifiersGDUFA Facility Business Operation Qualifiers
valueset-gdufaFacilityBusinessOperationsGDUFA Facility Business Operations
valueset-labelerBusinessOperationsLabeler Business Operations
valueset-splColorSPL Color
valueset-splComboProductTypeSPL Combo Product Type
valueset-splDoseFormSPL Dose Form
valueset-splFlavorSPL Flavor
valueset-splMarketingCategoriesSPL Marketing Categories
valueset-splOperationTypeSPL Operation Type
valueset-splPackageTypesSPL Package Types
valueset-splRouteOfAdministrationSPL Route of Administration
valueset-splShapeSPL Shape
valueset-splSpecialMeasuresSPL Special Measures
capsule-classification-categoryCapsule Shell Classification Terminology
cmc-product-name-types-vsProduct Name Types Terminology
pqcmc-batch-utilization-terminologyBatch utilization Terminology
pqcmc-chemical-structure-datafile-type-terminologyChemical Structure Data File Type Terminology
pqcmc-closure-type-terminologyClosure Type Terminology
pqcmc-coating-purposeCoating Purpose Terminology
pqcmc-container-type-terminologyContainer Type Terminology
pqcmc-drug-product-component-function-category-terminologyDrug Product Component Function Category Terminology
pqcmc-excipient-function-terminologyExcipient Function Terminology
pqcmc-impurity-classification-terminologyImpurity Classification Terminology
pqcmc-manufactured-dose-form-terminologyManufactured Dose Form Terminology
pqcmc-product-part-ingredient-physical-locationIngredient Location Terminology
pqcmc-product-part-typeProduct Part Type Terminology
pqcmc-quality-benchmark-terminologyQuality Benchmark Terminology
pqcmc-release-mechanismRelease Mechanism Terminology
pqcmc-release-profileRelease Profile Terminology
pqcmc-representation-typesRepresentation Types
pqcmc-source-type-terminologySource Type Terminology
pqcmc-specification-status-terminologySpecification Status Terminology
pqcmc-specification-type-terminologySpecification Type Terminology
pqcmc-strength-type-terminologyStrength Type Terminology
pqcmc-substance-name-typeSubstance Name Type
pqcmc-test-category-terminologyTest Category Terminology
pqcmc-test-method-origin-terminologyTest Method Origin Terminology
pqcmc-test-usage-terminologyTest Usage Terminology
spl-drug-route-of-administration-terminologyDrug Route Of Administration Terminology
spl-pharmaceutical-dosage-form-terminologyPharmaceutical Dosage Form Terminology
substance-classificationSubstance Classification
molecular-biomarker-code-vsMolecular Biomarker Codes
nfdi4health-vs-mds-cd-datacollected-nciNFDI4Health Data Collected [NCI]
nfdi4health-vs-mds-cd-information-sources-nci-localNFDI4Health Data Collected [NCI]
nfdi4health-vs-mds-id-type-nci-localNFDI4Health VS MDS ID Type [NCI, local]
nfdi4health-vs-mds-identifier-type-related-artifact-nci-localNFDI4Health VS MDS Identifier Type Related Artifact [NCI, local]
nfdi4health-vs-mds-mortality-data-nciNFDI4Health VS MDS Mortality Data [NCI]
nfdi4health-vs-mds-ne-instrument-nci-localNFDI4Health NE Instrument [NCI, Local]
nfdi4health-vs-mds-ne-mode-nci-msh-localNFDI4Health NE Mode [NCI, MeSH, Local]
nfdi4health-vs-mds-organisational-roles-nci-localNFDI4Health VS MDS Organisational Roles [NCI, local]
nfdi4health-vs-mds-personal-roles-nci-localNFDI4Health VS MDS Personal Roles [NCI, local]
nfdi4health-vs-mds-population-coverage-nciNFDI4Health VS MDS Population Coverage [NCI]
nfdi4health-vs-mds-resource-type-general-nci-msh-localNFDI4Health VS MDS Resource Type General [NCI, MSH, local]
nfdi4health-vs-mds-resource-type-nci-localNFDI4Health VS MDS Resource Type [NCI, Local]
nfdi4health-vs-mds-study-allocation-nciNFDI4Health VS MDS Study Allocation [NCI]
nfdi4health-vs-mds-study-arm-group-type-nciNFDI4Health VS MDS Study Arm Group Type [NCI]
nfdi4health-vs-mds-study-assessments-sct-nciNFDI4Health VS MDS Study Assessments [SCT, NCI]
nfdi4health-vs-mds-study-biospecimen-retention-nciNFDI4Health VS MDS Study Biospecimen Retention [NCI]
nfdi4health-vs-mds-study-conditions-classification-nci-localNFDI4Health VS MDS Study Conditions Classification [NCI, Local]
nfdi4health-vs-mds-study-data-sharing-plan-ds-sct-nciNFDI4Health VS MDS Study Data Sharing Plan Datashield [SCT, NCI]
nfdi4health-vs-mds-study-data-sharing-plan-sup-inf-nci-localNFDI4Health VS MDS Study Data Sharing Plan Supporting Information [NCI, local]
nfdi4health-vs-mds-study-data-sources-general-nci-localNFDI4Health VS MDS Study Data Sources General [NCI, local]
nfdi4health-vs-mds-study-data-sources-imaging-nciNFDI4Health VS MDS Study Data Sources Imaging [NCI]
nfdi4health-vs-mds-study-data-sources-omics-nciNFDI4Health VS MDS Study Data Sources Omics [NCI]
nfdi4health-vs-mds-study-ds-biosamples-sct-nciNFDI4Health VS MDS Study Data Sources Biosamples [SCT, NCI]
nfdi4health-vs-mds-study-ethics-committee-approval-nci-localNFDI4Health VS MDS Study Ethics Commitee Approval [NCI, local]
nfdi4health-vs-mds-study-exposure-type-nciNFDI4Health VS MDS Study Exposure Type [NCI]
nfdi4health-vs-mds-study-group-characteristics-nciNFDI4Health VS MDS Study Group Characteristics [NCI]
nfdi4health-vs-mds-study-intervention-type-nciNFDI4Health VS MDS Study Intervention Type [NCI]
nfdi4health-vs-mds-study-masking-roles-nci-localNFDI4Health VS MDS Study Masking Roles [NCI, local]
nfdi4health-vs-mds-study-outcome-type-nciNFDI4Health VS MDS Study Outcome Type [NCI]
nfdi4health-vs-mds-study-overall-status-nci-localNFDI4Health VS MDS Study Overall Status [NCI, Local]
nfdi4health-vs-mds-study-phase-nciNFDI4Health VS MDS Study Phase [NCI]
nfdi4health-vs-mds-study-primary-design-nciNFDI4Health VS MDS Study Primary Design [NCI]
nfdi4health-vs-mds-study-primary-purpose-hl7-nciNFDI4Health VS MDS Study Primary Purpose [HL7, NCI]
nfdi4health-vs-mds-study-recruitment-register-nci-sct-localNFDI4Health VS MDS Study Recruitment Register [NCI, SCT, Local]
nfdi4health-vs-mds-study-sampling-method-nci-localNFDI4Health VS MDS Study Sampling Method [NCI, local]
nfdi4health-vs-mds-study-sampling-method-non-prob-nci-localNFDI4Health VS MDS Study Sampling Method Non Probability [NCI, local]
nfdi4health-vs-mds-study-sampling-prob-method-nci-localNFDI4Health VS MDS Study Sampling Probability Method [NCI, Local]
nfdi4health-vs-mds-study-time-perspectives-nciNFDI4Health VS MDS Study Time Perspectives [NCI]
nfdi4health-vs-mds-study-type-interventional-nciNFDI4Health VS MDS Study Type Interventional [NCI]
nfdi4health-vs-mds-study-type-non-interventional-nci-msh-localNFDI4Health VS MDS Study Type Non Interventional [NCI, MSH, local]
nfdi4health-vs-mds-yes-no-undecided-nciNFDI4Health VS MDS Yes, No, Undecided [ NCI]
adverse-event-clinical-research-causality-relatednessAdverse Event Clinical Research Causality Relatedness
adverse-event-clinical-research-gradesAdverse Event Clinical Research Grades
adverse-event-clinical-research-outcomesAdverse Event Clinical Research Outcomes
adverse-event-clinical-research-seriousness-criteriaAdverse Event Clinical Research Seriousness Criteria
deid-parameter-namesDe-identification Parameter Names
device-note-typesDevice Note Type Codes
2.16.840.1.113762.1.4.1021.30AdministrationUnitDoseForm
2.16.840.1.113762.1.4.1021.46Device Magnetic resonance (MR) Safety
2.16.840.1.113762.1.4.1021.47Device Latex Safety
2.16.840.1.113762.1.4.1021.48Implantable Device Status
2.16.840.1.113762.1.4.1032.292Non pharmacologic treatments for chronic pain NCI
2.16.840.1.113762.1.4.1032.36Non pharmacologic treatments for chronic pain
2.16.840.1.113762.1.4.1260.100MMR Proficient
2.16.840.1.113762.1.4.1260.11Estrogen Receptor Test for Orserdu
2.16.840.1.113762.1.4.1260.116Localized Bladder Cancer Staging
2.16.840.1.113762.1.4.1260.119Localized Bladder Cancer T Stage
2.16.840.1.113762.1.4.1260.128FGFR3 Gene
2.16.840.1.113762.1.4.1260.13HER2 Negative
2.16.840.1.113762.1.4.1260.131FGFR3 Gene Interpretation Positive NCI
2.16.840.1.113762.1.4.1260.133FGFR3 Gene Interpretation Positive
2.16.840.1.113762.1.4.1260.135FGFR3 Gene Interpretation Negative NCI
2.16.840.1.113762.1.4.1260.137FGFR3 Gene Interpretation Negative
2.16.840.1.113762.1.4.1260.138FGFR3 Molecular Variants
2.16.840.1.113762.1.4.1260.190Localized NSCLC Stage Group NCIM
2.16.840.1.113762.1.4.1260.192Localized NSCLC Stage Group
2.16.840.1.113762.1.4.1260.198EGFR Gene
2.16.840.1.113762.1.4.1260.203EGFR Generic Molecular Variant NCIM
2.16.840.1.113762.1.4.1260.206EGFR Molecular Variants Osimertinib PM
2.16.840.1.113762.1.4.1260.214Radiation Treatment Delivery NCIM
2.16.840.1.113762.1.4.1260.216Radiation Treatment Delivery
2.16.840.1.113762.1.4.1260.227MET Exon 14 skipping molecular variant
2.16.840.1.113762.1.4.1260.235ROS1 Repotrectinib Molecular Variants
2.16.840.1.113762.1.4.1260.237ROS1 Negative (geneinterpretation) NCI
2.16.840.1.113762.1.4.1260.238ROS1 Negative (geneinterpretation) SNOMEDCT,NCI
2.16.840.1.113762.1.4.1260.240ROS1 results (HGNC)
2.16.840.1.113762.1.4.1260.246RET Negative (geneinterpretaion) NCI
2.16.840.1.113762.1.4.1260.247RET Negative (geneinterpretaion) SNOMEDCT,NCI
2.16.840.1.113762.1.4.1260.248RET Fusion Molecular Variants
2.16.840.1.113762.1.4.1260.25ESR1 Gene Test
2.16.840.1.113762.1.4.1260.26ESR1 Genetic Mutation
2.16.840.1.113762.1.4.1260.260ALK Positive (geneinterpretation) NCI
2.16.840.1.113762.1.4.1260.261ALK Positive (geneinterpretation) SNOMEDCT NCI
2.16.840.1.113762.1.4.1260.263ALK Negative (geneinterpretation) NCI
2.16.840.1.113762.1.4.1260.264ALK Negative (geneinterpretation) SNOMEDCT NCI
2.16.840.1.113762.1.4.1260.277Extensive SCLC Stage Group NCIM
2.16.840.1.113762.1.4.1260.278Extensive SCLC Stage Group
2.16.840.1.113762.1.4.1260.28Her2 Negative
2.16.840.1.113762.1.4.1260.30HER2 Positive
2.16.840.1.113762.1.4.1260.305HER2 Negative (geneinterpretation/Labtestvalue) NCI
2.16.840.1.113762.1.4.1260.307HER2 Negative (geneinterpretation/Labtestvalue)
2.16.840.1.113762.1.4.1260.311Localized_Solid_Cancer_Stage Group NCIM
2.16.840.1.113762.1.4.1260.313Localized_Solid_Cancer_Stage Group
2.16.840.1.113762.1.4.1260.314Locally_Advanced_Solid_Cancer_Stage Group NCIM
2.16.840.1.113762.1.4.1260.315Locally_Advanced_Solid_Cancer_Stage Group
2.16.840.1.113762.1.4.1260.316Metastatic_Solid_Cancer_Stage Group NCIM
2.16.840.1.113762.1.4.1260.317Metastatic_Solid_Cancer_Stage Group
2.16.840.1.113762.1.4.1260.319Solid Cancer T Stage NCI
2.16.840.1.113762.1.4.1260.32HER2 Positive
2.16.840.1.113762.1.4.1260.320Solid Cancer T Stage codes
2.16.840.1.113762.1.4.1260.325RET fusion Molecular Variants_Solid_Cancer
2.16.840.1.113762.1.4.1260.344PTEN_gene
2.16.840.1.113762.1.4.1260.346PIK3CA_gene
2.16.840.1.113762.1.4.1260.348AKTI_gene
2.16.840.1.113762.1.4.1260.350Progesterone_receptor_gene
2.16.840.1.113762.1.4.1260.352Estrogen_receptor_gene
2.16.840.1.113762.1.4.1260.359HER2_IHC_test_Gene
2.16.840.1.113762.1.4.1260.372HER2 test_gene
2.16.840.1.113762.1.4.1260.416KRAS_G12C_MV
2.16.840.1.113762.1.4.1260.429Localized_Endometerial_Stage Group NCIM
2.16.840.1.113762.1.4.1260.460Localized_Endometerial_Stage Group_SNOMED/NCIM
2.16.840.1.113762.1.4.1260.465NTRK Repotrectinib Molecular Variants
2.16.840.1.113762.1.4.1260.55MSI High
2.16.840.1.113762.1.4.1260.57Early Stage IIB or lower
2.16.840.1.113762.1.4.1260.60MMR Deficient
2.16.840.1.113762.1.4.1260.61Stage IIB or lower and limited
2.16.840.1.113762.1.4.1260.63Stage III or higher
2.16.840.1.113762.1.4.1260.64Stage III or higher
2.16.840.1.113762.1.4.1260.66Staging Unknown
2.16.840.1.113762.1.4.1260.67Staging Unknown
2.16.840.1.113762.1.4.1260.84RAS Gene Interpretation Negative NCM
2.16.840.1.113762.1.4.1260.85RAS Gene Negative
2.16.840.1.113762.1.4.1260.9ER Test for Orserdu
2.16.840.1.113762.1.4.1260.91MSI High NCI
2.16.840.1.113762.1.4.1260.94MSI Low NCI
2.16.840.1.113762.1.4.1260.95MSI Low
2.16.840.1.113762.1.4.1260.96MMR Deficient NCI
2.16.840.1.113762.1.4.1260.99MMR Proficient NCI
2.16.840.1.113762.1.4.1267.22Route of Administration of Therapeutic Agents
2.16.840.1.113883.3.88.12.3221.8.11Medication Product Form
2.16.840.1.113883.3.88.12.3221.8.7SPL Drug Route of Administration Terminology
anforderung-liquidBiopsyValueSet - nNGM - Anforderung Liquid Biopsy
anforderung-molekularpathologieValueSet - nNGM - Anforderung Molekularpathologie
MaterialTypValueSet - nNGM - MaterialTyp
tki-resistenzValueSet - nNGM - TKI Resistenz

Resources that this resource uses

No resources found


Narrative

Note: links and images are rebased to the (stated) source

Generated Narrative: CodeSystem v3-nciThesaurus

This case-sensitive code system http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl defines codes, but no codes are represented here


Source

{
  "resourceType": "CodeSystem",
  "id": "v3-nciThesaurus",
  "text": {
    "status": "generated",
    "div": "<!-- snip (see above) -->"
  },
  "url": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
  "identifier": [
    {
      "system": "urn:ietf:rfc:3986",
      "value": "urn:oid:2.16.840.1.113883.3.26.1.1"
    }
  ],
  "version": "3.0.0",
  "name": "NciThesaurus",
  "title": "NCI Thesaurus",
  "status": "active",
  "experimental": false,
  "date": "2022-10-13T00:00:00-04:00",
  "publisher": "TBD - External Body",
  "contact": [
    {
      "name": "National Cancer Institute"
    }
  ],
  "description": "NCI Thesaurus NCI Thesaurus is a biomedical thesaurus created specifically to meet the needs of the cancer research community, especially those engaged in translational research NCI Thesaurus is produced by the NCI Enterprise Vocabulary Services project. The NCI Thesaurus is provided under an open content license.",
  "caseSensitive": true,
  "content": "not-present"
}